Veradermics, Incorporated (MANE)
| Market Cap | 3.90B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -83.37M |
| Shares Out | 37.34M |
| EPS (ttm) | -111.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,159,898 |
| Open | 95.00 |
| Previous Close | 100.10 |
| Day's Range | 95.00 - 109.96 |
| 52-Week Range | 32.00 - 109.96 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 83.33 (-20.18%) |
| Earnings Date | Mar 30, 2026 |
About MANE
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $83.33, which is a decrease of -20.18% from the latest price.
News
Veradermics Announces Launch of Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”) (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
Veradermics Inc. (NYSE:MANE) announced on Monday that its novel oral formulation, VDPHL01, achieved positive results in a Phase 2/3 trial for pattern hair loss.
Veradermics Transcript: Study result
Top-line results from a large phase II/III trial show VDPHL01 achieved significant hair growth and high patient satisfaction with a strong safety profile. Both once- and twice-daily regimens outperformed existing therapies, and market research indicates high intent to prescribe and use if approved.
Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair ...
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Transcript: Leerink Global Healthcare Conference 2026
A novel extended-release oral minoxidil tablet is advancing through phase III trials, showing rapid and robust hair growth with improved safety and convenience. The product targets a large, motivated market, leverages a strong IP portfolio, and is positioned for broad adoption through dermatology, primary care, and telehealth channels.
Veradermics to Participate in Upcoming March Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics Announces Pricing of Upsized Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics, Dermatology Biopharma Focused on Hair Loss, Files for NYSE IPO
Veradermics, a late-stage dermatology biopharma, filed an S-1 for an initial public offering...
Veradermics IPO Registration Document (S-1)
Veradermics has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Hair loss biotech Veradermics files for a $100 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering.